Subscribe
Core coverageRYTM

Company profile / RYTM

Rhythm Pharmaceuticals, Inc.

Clinaptis stanceCautious
ConvictionLow
Ticker
RYTM
Exchange
NASDAQ
Coverage
Standard profile
Updated
Sep 19, 2026
Rare Disease / Endocrinology / Obesity

Commercial-stage rare-neuroendocrine company built around melanocortin-4 receptor agonism. IMCIVREE (setmelanotide) is approved for acquired hypothalamic obesity in patients aged four years and older and for Bardet-Biedl syndrome and qualifying POMC, PCSK1 or LEPR deficiencies. Acquired hypothalamic obesity is now the principal growth driver. Oral bivamelagon and once-weekly injectable RM-718 are intended to extend the MC4R franchise through greater convenience and longer intellectual-property duration, with Prader-Willi syndrome and congenital hypothalamic obesity providing additional indication-expansion options.

01 / Clinaptis view

The current read

Initial read: clinically constructive, valuation cautious. TRANSCEND settled the efficacy question: setmelanotide reduced BMI by 16.5% at one year versus a 3.3% gain on placebo, a 19.8-point placebo-adjusted difference, and 80% of treated patients achieved at least 5% BMI reduction.

  1. The U.S. launch also began strongly, with more than 400 patient-start forms from roughly 300 prescribers in the first 14 weeks. Those facts establish physician demand; they do not yet establish the mature revenue curve.
  2. Sixty-six forms were trial conversions, approximately half of early patients had sustained hypothalamic injury more than ten years earlier, and Rhythm has not disclosed the full forms-to-paid-patient funnel or mature persistence. This is a backlog-heavy orphan launch in which start forms, ever-started patients and reimbursed patient-years are different measures.
  3. Our September 11 valuation work used an approximately $8.0 billion fully diluted enterprise value and produced a $4.79 billion central enterprise value, or roughly $63 per share after net cash. Even 6,000 eventual prevalent U.S. starts plus approximately 500 annual incident cases reached only about $91 per share under Base economics.
  4. Reaching the note's $104.71 reference price required the upper end of commercial assumptions: roughly 6,000 prevalent starts, about 500 annual incident cases, 90% or better persistence and durable post-2034 economics. The clinical case is made; the security thesis is now a low-conviction valuation call on patient capture, duration and lifecycle value.
02 / Consensus gap

Where the market may differ

The bullish read treats the 2026 approvals as the creation of a new commercial category. Acquired-HO patients are unusually identifiable for a rare disease, TRANSCEND showed large controlled efficacy, early payer access has not required GLP-1 failure and the first 14 weeks demonstrated broad prescriber interest.

  1. On that view, the approximately 10,000-patient U.S. epidemiologic estimate, ex-U.S. expansion and an oral successor support the current valuation. The cautious read separates a strong launch from a proven steady state.
  2. Early forms harvest a finite prevalent backlog, while mature value depends on paid conversion, annual incident flow and persistence. In the Clinaptis cohort model, 3,000 eventual prevalent starts support roughly $63 per share; the formal Bull reaches about $79, and 6,000 prevalent starts plus approximately 500 annual incident cases reach about $91 before adding higher persistence and stronger post-2034 durability.
  3. The market may also be valuing bivamelagon and RM-718 as both incremental growth and patent extension even though much of their economic role is likely to be migration of the same patients. The disagreement is therefore not whether IMCIVREE works.
  4. It is whether an epidemiologic prevalence estimate becomes a durable, reimbursed patient-year denominator large enough to support an already demanding valuation.
Coverage state
Standard profile
What the review turns on
Key variable

Durable paid patient-years in acquired hypothalamic obesity: the conversion of start forms into reimbursed patients, annual persistence after the prevalent backlog is worked through and the recurring incident-patient flow

Next catalyst

IMCIVREE · 3Q26 U.S. acquired-HO commercial update, with paid conversion, recognized demand, repeat prescribing and early persistence more informative than gross start forms; Bivamelagon · pivotal acquired-HO Phase 3 initiation and final design · by year-end 2026

03 / Pipeline

Key programs

5 assets · 7 programs

AssetIndicationStageNext event
IMCIVREE (setmelanotide)
Acquired hypothalamic obesity
Commercial in the U.S., EU, UK and Japan
3Q26 U.S. launch update; track paid conversion, active reimbursed patients, demand net of inventory, repeat prescribing, discontinuation and injury-date mix. Japanese launch is expected after pricing by year-end 2026, with European country launches beginning in 2027
Bardet-Biedl syndrome and obesity due to qualifying POMC, PCSK1 or LEPR deficiencies
Commercial
Quarterly patient growth, reimbursement conversion and persistence across the established genetic-obesity franchise
Bivamelagon
Acquired hypothalamic obesity
Phase 2 completed / pivotal Phase 3 preparation
Pivotal Phase 3 initiation by year-end 2026; final dose, endpoint, duration, background-therapy rules and tolerability will determine whether the oral successor can preserve efficacy and extend franchise duration
RM-718
Acquired hypothalamic obesity
Phase 1/2
Additional efficacy, durability and safety data; weekly convenience must be weighed against the small early denominator, injection-site reactions and adverse-event discontinuations
Setmelanotide
Congenital hypothalamic obesity
Randomized Phase 3 TRANSCEND substudy
Enrollment completion expected in 2H26 and subsequent readout timing
Prader-Willi syndrome
Exploratory Phase 2 completed
Randomized-development decision after small open-label weight, hyperphagia and body-composition signals
RM-718
Prader-Willi syndrome
Phase 1/2
Part D enrollment completion expected in 2H26; initial efficacy disclosure timing has not been confirmed
04 / Connected research

Published on RYTM

View full archive
  1. 01

    Rhythm (RYTM): The Price of a Strong Rare-Obesity Launch

    The acquired-HO launch is strong, but our cohort model implies ~$63 per share at Base and shows how much patient capture, persistence and post-2034 durability the ~$8B valuation already requires.

    Read